Research activity information

• Nov. 2018 日本薬学会 医薬化学部会, Award for Excellent Presentation, 36th Medicinal Chemistry Symposium, DMC, PSJ in 2018, 世界最強の作用を有するCETP阻害剤TA-8995(obicetrapib)の創製

  林則充, 窪田均, 中村恵宣, 山元康王, 菅原正克, 東島孝典, 大井真利子, 岡幸蔵

• A Semantic Data Model (SDM)–Based Data Warehouse as a Common Platform for a Regional Integrated Biobank Network: Prototype Design and Construction

  oshinori Nakamur, Hideo Suzuki, Kohei Morimo, Takaichi Okano, Itsuko Sato, Akiko Fujiwar, Sadatoshi Kobayashi, Hirofumi Ueki, Tomoko Yamaguchi, Eiichi Maed, Yoshihiro Muragaki, Hiroshi Matsuok

  Lead, Aug. 2026, Mumps, Japanese

  [Refereed]


• Exploring vertical genomic heterogeneity and chemotherapy response using targeted genomic sequencing in muscle-invasive bladder cancer

  Taisuke Tobe, Yoshiharu Miyata, Yoshinori Nakamura, Takuto Hara, Tomoaki Terakawa, Jun Teishima, Koji Chiba, Takayuki Kodama, Takanori Hasegawa, Naoto Kondo, Toshiyuki Sato, Hideaki Miyake, Raizo Yamaguchi, Hiroshi Matsuoka

  Springer Science and Business Media LLC, Aug. 2026, BMC Urology

  [Refereed]

  Scientific journal


• Pleuroparenchymal fibroelastosis-like findings identify an idiopathic pulmonary fibrosis subgroup with shortened telomeres and poor prognosis

  Ryota Otoshi, Hideya Kitamura, Takashi Niwa, Kota Murohashi, Tsuneyuki Oda, Tomohisa Baba, Eri Hagiwara, Tae Iwasawa, Tamiko Takemura, Koji Okudela, Yosui Nojima, Yoshinori Nakamura, Kenji Mizuguchi, Yayoi Natsume-Kitatani, Takashi Ogura

  Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD) with poor prognosis. Radiological pleuroparenchymal fibroelastosis (PPFE)-like findings, characterised by upper-lobe subpleural fibrosis, have been associated with worse outcome in IPF. While short leukocyte telomere length (LTL) is a recognised prognostic factor, its relationship with PPFE-like findings remains unclear. Methods We conducted a secondary analysis of an ongoing ILD cohort. IPF patients who underwent LTL measurement by quantitative PCR were classified into those with PPFE-like findings on high-resolution computed tomography (IPF/PPFE group) and those without such findings (IPF/usual interstitial pneumonia (UIP) group). Clinical characteristics, pulmonary function, telomere length and outcomes were compared. Age-adjusted LTL was evaluated using healthy controls. Prognostic factors were analysed using Cox regression. Results Among 179 IPF patients, 29 (16%) were assigned to the IPF/PPFE group. Compared to the IPF/UIP group (n=150), the IPF/PPFE group had lower body mass index and forced vital capacity, and significantly shorter LTL (p=0.002), with more patients below the 10th percentile of healthy controls (37.9% versus 12.0%). The IPF/PPFE group showed greater respiratory functional decline and higher mortality (65.5% versus 25.3%, p<0.001). In survival analysis, both PPFE-like findings and shortened LTL predicted worse outcomes; however, only PPFE-like findings remained independently associated with mortality in multivariate analysis. Conclusions IPF patients with PPFE-like findings constitute a distinct high-risk phenotype with shorter telomeres, accelerated progression, and poor prognosis. These findings highlight the clinical importance of recognising PPFE-like changes and telomere biology in IPF for risk stratification and emphasise the need for close monitoring and early intervention.

  European Respiratory Society (ERS), Feb. 2026, ERJ Open Research, 12(4) (4), 01619 - 2025

  [Refereed]

  Scientific journal


• Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML

  Mayu Ikeda, Hikaru Hattori, Yuki Namba, Yuji Izumisawa, Motonari Daito, Takaichi Okano, Kohei Morimoto, Yoshinori Nakamura, Kimikazu Yakushijin, Hironobu Minami, Hiroshi Matsuoka

  Abstract Background In patients diagnosed with AML, the implementation of leukemia gene testing in accordance with the ELN 2022 guidelines is of paramount importance for the stratification of prognoses, thereby facilitating the determination of optimal treatment strategies. Presently, comprehensive NGS-based methods are extensively employed for these classifications; however, implementing them globally, including in Japan, is constrained by several factors in daily clinical practice, such as cost per sample, turn-around time, and technical hurdles in quality control. Aims The objective of this study was to develop a cost-effective screening system capable of simultaneously screening multiple genes necessary for prognostic stratification of known targets. In the previous report, we selected three specific mutations: NPM1 mutations, FLT3-ITD mutations, and in-frame indel mutations in the bZIP domain of the CEBPA and developed assay panel. Since these mutations can be detected based on the length of DNA fragments, we adopted a multiplex fragment analysis method using a capillary electrophoresis sequencer (CES), which is cost-effective, highly sensitive and competent for various length of fragments. Methods We assessed the clinical performance of our assay panel measured 53 de novo AML patient samples (median age, 66 years; 36 males and 18 females). We employed the Sanger sequencing method as a control method. We detected the presence or absence of each mutation in the patient samples and calculated the percentage of agreement with the Sanger sequencing analysis. Clinical samples were obtained from Bioresource Center, Kobe University Hospital in accordance with the Declaration of Helsinki and under an approved Kobe University institutional research protocol (B240242). Results We confirmed 100% accuracy in comparison with the Sanger sequencing, which is the control method. The breakdown of mutations contained in clinical samples was as follows: 12 samples with NPM1 mutations, 11 samples with FLT3-ITD mutations, and 1 sample with in-frame indel mutations in the bZIP domain of the CEBPA, although the number of positive results includes duplicate calculations for samples containing multiple genetic mutations. For samples with a low mutation allelic ratio, the presence of mutations was confirmed, but they were below the sensitivity of the Sanger sequencing and could not be sequenced. Also, it was found that some FLT3-ITD mutation-positive samples contained ITDs of multiple sizes, with up to four different sizes (63, 69, 84, and 175 bp) of ITDs identified. Discussion In our previous report, it was demonstrated that the assay panel achieved 100% accuracy in agreement with Sanger sequencing when using simulated samples created by mixing synthetic genes with healthy human peripheral blood mononuclear cells, and detected mutations at a rate of 2.9%. In this clinical evaluation, utilizing real patient's cells, the method exhibited substantial agreement with the control method, thereby reinforcing its efficacy. It is noteworthy that even low-frequency variants were effectively identified. This case suggests that the assay panel may be useful for classifying the disease appropriately and determining treatment strategies in MDS with a tumor content of less than 20%, based on the 5th edition of the WHO classification. Furthermore, the test demonstrated an adequate capability to detect samples with multiple FLT3-ITDs of multiple sizes. Due to the inherent characteristics of NGS technology, the detection and annotation of these types of mutation remain intricate, and the design of primers that are specific to each mutation in qPCR is an arduous task. Conclusion The three-gene assay panel using our developed fragment analysis system in CES was able to detect the mutations of three key genes that can be used for minimum decision-making to perform prognosis stratification of de novo AML in accordance with current ELN guidelines in a manner that is rapid, highly sensitive, and cost-effective in comparison to NGS. Additionally, it can handle a wide range of mutation patterns without customization, a feature that distinguishes it from qPCR. We consider that this will enable rapid risk stratification prior to standard treatment to be provided to clinical settings in diverse regions around the world.

  American Society of Hematology, Nov. 2025, Blood, 146(Supplement 1) (Supplement 1), 7854 - 7855

  Scientific journal


• Palladium-Catalyzed Coupling of Functionalized Primary and Secondary Amines with Aryl and Heteroaryl Halides: Two Ligands Suffice in Most Cases.

  Debabrata Maiti, Brett P Fors, Jaclyn L Henderson, Yoshinori Nakamura, Stephen L Buchwald

  We report our studies on the use of two catalyst systems, based on the ligands BrettPhos (1) and RuPhos (2), which provide the widest scope for Pd-catalyzed C-N cross-coupling reactions to date. Often low catalyst loadings and short reaction times can be used with functionalized aryl and heteroaryl coupling partners. The reactions are highly robust and can be set up and performed without the use of a glovebox. These catalysts should find wide application in the synthesis of complex molecules including pharmaceuticals, natural products and functional materials.

  Jan. 2011, Chemical science, 2(1) (1), 57 - 68, English, International magazine

  [Refereed]

  Scientific journal


• 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.

  Tatsuzo Ukita, Yoshinori Nakamura, Akira Kubo, Yasuo Yamamoto, Yasunori Moritani, Kunio Saruta, Takanori Higashijima, Jun Kotera, Kotomi Fujishige, Michino Takagi, Kohei Kikkawa, Kenji Omori

  Novel 1,7- and 2,7-naphthyridine derivatives, designed by the introduction of nitrogen atom into the phenyl ring of previously reported 4-aryl-1-isoquinolinone derivatives, were disclosed as a new structural class of potent and specific PDE5 inhibitors. Among them, 2,7-naphthyridine 4c showed potent PDE5 inhibition (IC(50)=0.23 nM) and one of the best PDE5 specificities against PDEs1-4,6 (>100,000-fold selective versus PDE1-4, 240-fold selective vs PDE6). This compound showed more potent relaxant effects on isolated rabbit corpus cavernosum (EC(30)=5.0 nM) than Sildenafil (EC(30)=8.7 nM). The compound 4c (T-0156) was selected for further biological and pharmacological evaluation of erectile dysfunction.

  Jul. 2003, Bioorganic & medicinal chemistry letters, 13(14) (14), 2341 - 5, English, International magazine

  [Refereed]

  Scientific journal


• Construction of heterocyclic compounds by use of alpha-diazophosphonates: new one-pot syntheses of indoles and isocoumarins.

  Yoshinori Nakamura, Tatsuzo Ukita

  [reaction: see text] alpha-Diazophosphonates, which have extremely useful properties from a synthetic point of view, are disclosed as 1,1-ambiphilic one-carbon building blocks for one-pot construction of various heterocyclic compounds. They are easily prepared and have higher stability by the effect of the phosphoryl group than corresponding alpha-diazocarbonyl compounds. Using this synthon, we have developed a novel, mild, and efficient synthetic method of 2,3-disubstituted indoles and 3,4-disubstituted isocoumarins.

  Jul. 2002, Organic letters, 4(14) (14), 2317 - 20, English, International magazine

  Scientific journal


• Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.

  T Ukita, Y Nakamura, A Kubo, Y Yamamoto, Y Moritani, K Saruta, T Higashijima, J Kotera, M Takagi, K Kikkawa, K Omori

  A novel class of potent and selective phosphodiesterase 5 (PDE5) inhibitors, 4-aryl-1-isoquinolinone derivatives, which have been designed by the comparison of the structure of cGMP and a previously reported 1-arylnaphthalene lignan, was disclosed. Among these compounds, methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate dihydrochloride (36a) exhibited potent PDE5 inhibitory activity (IC(50) = 1.0 nM) with high isozyme selectivities (IC(50) ratio: PDE1/PDE5 = 1300, PDE2/PDE5 > 10 000, PDE3/PDE5 > 10 000, PDE4/PDE5 = 4700, PDE6/PDE5 = 28). Compound 36a also showed the most potent relaxant effect on isolated rabbit corpus cavernosum (EC(30) = 7.9 nM). Compound 63 (T-1032), the sulfate form of 36a, was selected for further biological and pharmacological evaluation of erectile dysfunction.

  Jun. 2001, Journal of medicinal chemistry, 44(13) (13), 2204 - 18, English, International magazine

  [Refereed]

  Scientific journal


• Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5).

  J Kotera, K Fujishige, H Michibata, K Yuasa, A Kubo, Y Nakamura, K Omori

  An isoquinolone derivative, methyl-2-(4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), was found to be a novel potent inhibitor of cyclic GMP (cGMP)-binding cGMP-specific phosphodiesterase (PDE5). We investigated the inhibitory effects of T-1032 on six PDE isozymes isolated from canine tissues. T-1032 specifically inhibited the hydrolysis of cGMP by PDE5 partially purified from canine lung, at a low concentration (IC(50) = 1.0 nM, K(i) = 1.2 nM), in a competitive manner. In contrast, the IC(50) values of T-1032 for PDE1, PDE2, PDE3, and PDE4 were more than 1 microM. T-1032 also inhibited PDE6 from canine retina with an IC(50) of 28 nM, which is of the same order of magnitude as the IC(50) of sildenafil. cGMP hydrolytic activities of two alternative splice variants of canine PDE5 expressed in COS-7 cells were inhibited by this compound to a similar extent. T-1032 increased the intracellular concentration of cGMP in cultured rat vascular smooth muscle cells in the presence and absence of C-type natriuretic peptide, an activator of membrane-bound guanylate cyclase, whereas the compound did not change cyclic AMP levels. These data indicated that T-1032, which belongs to a new structural class of PDE5 inhibitors, is a potent and selective PDE5 inhibitor. This compound may be useful in pharmacological studies to examine the role of a cGMP/PDE5 pathway in tissues.

  Nov. 2000, Biochemical pharmacology, 60(9) (9), 1333 - 41, English, International magazine

  [Refereed]

  Scientific journal


• 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.

  T Ukita, Y Nakamura, A Kubo, Y Yamamoto, M Takahashi, J Kotera, T Ikeo

  1-Arylnaphthalene lignan, which had been reported as a PDE4 inhibitor by Iwasaki, was disclosed as a new structural class of PDE5 inhibitors. The structural requirements for potent and specific PDE5 inhibition were revealed in a 1-arylnaphthalene lignan series, in which 1-(3-bromo-4, 5-dimethoxyphenyl)-5-chloro-3-[4-(2-hydroxyethyl)-1-piperazinylcarbon yl]-2-(methoxycarbonyl)naphthalene hydrochloride (27q) showed the most potent and specific inhibition (PDE5 inhibition IC50 = 6.2 nM, selectivity for PDE5 against PDE1, -2, -3, and -4 >16 000). It is noteworthy that 27q has the best selectivities against PDE isoforms among PDE5 inhibitors so far reported. Compound 27q exhibited almost the same relaxant effects on rat aortic rings as sodium 1-[6-chloro-4-[(3, 4-methylenedioxybenzyl)amino]quinazolin-2-yl]piperidine-4-ca rboxylate (35) (27q, EC50 = 0.10 microM; 35, EC50 = 0.20 microM) and was selected for further biological evaluation.

  Apr. 1999, Journal of medicinal chemistry, 42(7) (7), 1293 - 305, English, International magazine

  [Refereed]

  Scientific journal


• Synthesis of a novel chiral 1, 3-benzoxazinone auxiliary and its application to highly diastereoselective aldol reaction

  Tsutomu Miyake, Masahiko Seki, Yoshinori Nakamura, Hiroshi Ohmizu

  Elsevier BV, Apr. 1996, Tetrahedron Letters, 37(18) (18), 3129 - 3132

  [Refereed]

  Scientific journal


• Convenient syntheses of oligonucleotides linked to 5-deazaflavin coenzyme models at 3'-end. Incorporation of 5-deazaflavin to controlled pore glass (CPG) support.

  Y Nakamura, T Akiyama, K Bessho, F Yoneda

  Using CPG support linked with 5-deazaflavin, the 5-deazaflavin modified oligodeoxynucleotides at 3'-end(ODN-dF1) were synthesized. The thermal stability of the duplex of ODN-dF1 with its complement was higher than that of oligonucleotide linked to 5-deazaflavin at 5'-end internucleotide linkage.

  Lead, Jul. 1993, Chemical & pharmaceutical bulletin, 41(7) (7), 1315 - 7, English, Domestic magazine

  [Refereed]

  Scientific journal


• Redox potential of oligonucleotide linked to 5-deazaflavin coenzyme model. Detection of hybrid formation by cyclic voltammometry.

  Y Nakamura, T Akiyama, Y Yoneda, K Tanaka, F Yoneda

  Lead, Apr. 1993, Chemical & pharmaceutical bulletin, 41(4) (4), 778 - 80, English, Domestic magazine

  [Refereed]

  Scientific journal


• Hybiridization of Oligodeoxynucleotide with Redox Coenzyme Model; Synthesis and Properties of Thymidine Decamers Covalently Linked to 5-Deazaflavin

  EIKYU Yoshiteru, NAKAMURA Yoshinori, AKIYAMA Taishin, YONEDA Fumio, TANAKA Kiyoshi, FUJI Kaoru

  Modified thymidine decamers covalently linked to 5-deazaflavin derivatives through aminoalkyl spacer arm in the form of phosphoramidate bond, were prepared and characterized, Chemical and physical properties of the hydrid moleculeas are discussed.

  The Pharmaceutical Society of Japan, Jan. 1992, Chemical & pharmaceutical bulletin, 40(1) (1), 291 - 293, English

  [Refereed]

• 第10回薬学の未来を考える京都シンポジウム開催報告

  中村恵宣

  Oct. 2025, 京大薬友会誌, 77, 16 - 17


• Construction of the platform to explore drug target for IPF in Public/Private R&D Investment Strategic Expansion PrograM（PRISM）

  Nakamura Yoshinori, Kitamura Hideya, Ogura Takashi, Natsume-Kitatani Yayoi, Mizuguchi Kenji

  National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) and Kanagawa Cardiovascular and Respiratory Center have built an integrated multi-omics database that constitutes the world’s largest medical information repository for Idiopathic pulmonary fibrosis (Kanagawa Cohort Database) in Public/Private R&D Investment Strategic Expansion PrograM (PRISM). NIBIOHN have also developed AI for the data-driven exploration of drug targets by stratifying patients based on clinical and omics data (comprehensive biomolecular information). In addition to AI to explore drug targets, organizations participating in PRISM have also developed tools for the analysis of clinical text, automatic knowledge extraction, and automatic inference system. NIBOHN plan to launch an open platform to allow researchers both in industry and academia to widely use these systems in FY2022.

  The Pharmaceutical Society of Japan, 01 Aug. 2022, Medchem News, 32(3) (3), 119 - 123, Japanese


• Building an innovative platform for identifying new drug discovery targets using clinical omics data and artificial intelligence

  榑林陽一, 夏目やよい, 進藤順紀, 中村恵宣, 川井享代

  2022, Pharm Tech Japan, 38(8) (8)


• Discovery of TA-8995 (obicetrapib) as a CETP Inhibitor

  Hayashi Norimitsu, Kubota Hitoshi, Nakamura Yoshinori, Yamamoto Yasuo, Oka Kozo

  Cholesteryl Ester Transfer Protein (CETP) inhibitors are expected to have anti-atherosclerotic effects by inducing favorable changes in lipoprotein profiles, such as increased HDL-C and decreased LDL-C. In the course of our exploration of structure-activity-relationship based on torcetrapib, “in vivo method that focused on drug development in conventional formulations” and “in vitro method that reflected the effects of in vivo experiments so well” were conducted. As a result, it was found that the carboxylic acid derivatives possessed promising pharmacological effects. After further optimization of carboxylic acid, we successfully discovered highly potent compound TA-8995 (obicetrapib) as a clinical candidate. In the recent clinical studies, TA-8995 showed the strongest LDL-C lowering and HDL-C raising effects in the class of CETP inhibitors.

  The Pharmaceutical Society of Japan, 01 Aug. 2019, Medchem News, 29(3) (3), 128 - 132, Japanese


• 〜AMEDにおける創薬などの支援の取組について〜 part.1 創薬等ライフサイエンス研究支援基盤事業について

  中村恵宣

  Lead, Sep. 2017, JAPIC NEWS, 401, 8 - 9, Japanese

  [Invited]


• MIT Buchwald研での研究とボストン留学生活

  中村恵宣

  Lead, 2009, Organometallic News, 58 - 59, Japanese

  [Invited]


• 医薬化学 hERG阻害の回避に向けた理論的な薬物分子設計は可能か?

  中村恵宣

  公益社団法人 日本薬学会, 2007, ファルマシア, 43(6) (6), 577 - 578, Japanese

• バイオバンクにおける臨床検査技師の役割

  勝亦 柚衣, 佐藤 伊都子, 森本 耕平, 白杉 郁, 中村 恵宣, 今西 孝充, 千藤 荘, 松岡 広

  第65回日臨技近畿支部医学検査学会, Sep. 2026, Japanese

  Oral presentation


• バイオバンクにおける検査部連携の重要性

  勝亦 柚衣, 佐藤 伊都子, 森本 耕平, 白杉 郁, 中村 恵宣, 今西 孝充, 千藤 荘, 松岡 広

  第11回クリニカルバイオバンク学会シンポジウム, Jul. 2026, Japanese

  Poster presentation


• バイオバンクにおける臨床検査室の役割：ISO20387とISO15189の協奏

  中村 恵宣

  第47回染色体遺伝子検査基礎技術セミナー, Jun. 2026, Japanese

  Invited oral presentation


• Impact of In Vitro Activated Coagulation as a Pre-Analytical Error on Coagulation and Fibrinolysis Test Results

  Akiyo Kawamoto, Eri Adachi, Keisuke Nishi, Takeshi Suzuki, Nobuo Arai, Hiroshi Kurono, Kaho Kurashima, Itsuko Sato, Tomoya Fukuoka, Ruri Kono, Kohei Morimoto, Yoshinori Nakamura, Yoshiharu Miyata, Takamitsu Imanishi, Yoshihiko Yano, Hiroshi Matsuoka

  39th International Symposium on Technical Innovations in Laboratory Hematology, Apr. 2026

  Poster presentation


• Machine Learning-Based Detection of In-Vitro Activated Coagulation Using APTT Clotting Curves

  Keisuke Nishi, Akiyo Kawamoto, Eri Adachi, Takesh Suzuki, Nobuo Arai, Hiroshi Kurono, Kaho Kurashima, Itsuko Sato, Tomoya Fukuoka, Ruri Kono, Kohei Morimoto, Yoshinori Nakamura, Yoshiharu Miyata, Takamitsu Imanishi, Yoshihiko Yano, Hiroshi Matsuoka

  39th International Symposium on Technical Innovations in Laboratory Hematology, Apr. 2026

  Poster presentation


• 【学術】バイオバンクにおける医療情報の二次利用 Semantic Data Model(SDM)に基づくデータウェアハウスの構築と利活用(Biobanks Leveraging Medical Information: Constructing and Utilizing a Semantic Data Model(SDM)-Based Data Warehouse)

  中村 恵宣

  医療情報学連合大会論文集, Nov. 2025, Japanese, (一社)日本医療情報学会

  Public symposium


• Pilot Design and Construction of a Data Warehouse Based on a Semantic Data Model (SDM) for Regional Integration of Virtual Biobank Networks

  Yoshinori Nakamura, Hideo Suzuki, Kohei Morimoto, Takaichi Okano, Itsuko Sato, Akiko Fujiwara, Sadatoshi Kobayashi, Hirofumi Ueki, Tomoko Yamaguchi, Eiichi Maeda, Yoshihiro Muragaki, Hiroshi Matsuoka

  第53回日本Mテクノロジー学会大会, Oct. 2025


• 自動搬送ラインを活用した検体処理プロセスの安定性評価とバイオリソース提供における品質担保

  金 貞姫, 佐藤 伊都子, 勝亦 柚衣, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 松岡 広, 千藤 荘

  医療検査と自動化, Aug. 2025, Japanese, (一社)日本医療検査科学会


• 病院併設型バイオバンクにおける全血残余検体の収集・提供体制の評価

  勝亦 柚衣, 金 貞姫, 佐藤 伊都子, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 千藤 荘, 松岡 広

  医療検査と自動化, Aug. 2025, Japanese, (一社)日本医療検査科学会


• ISO20387取得への歩みと今後の展望

  岡野 隆一, 佐藤 伊都子, 勝亦 柚衣, 金 貞姫, 林 ひろ子, 藤原 明子, 森本 耕平, 中村 恵宣, 松岡 広

  第10回クリニカルバイオバンク学会シンポジウム, Jul. 2025


• APTT凝固波形の機械学習による採血管内凝固検出アルゴリズムの構築

  西 圭祐, 田渕 有香, 川本 明代, 松野 衣里子, 鈴木 健史, 新井 信夫, 黒野 浩司, 倉島 佳歩, 佐藤 伊都子, 福岡 知也, 河野 瑠璃, 森本 耕平, 中村 恵宣, 宮田 吉晴, 今西 孝充, 矢野 嘉彦, 松岡 広

  日本臨床検査医学会誌, Jul. 2025, Japanese, (一社)日本臨床検査医学会


• Fib4 indexは関節リウマチ患者においてMTX継続率を予想する

  岡野 隆一, 佐藤 伊都子, 中村 恵宣, 松岡 広, 千藤 荘, 三枝 淳

  日本臨床検査医学会誌, Jul. 2025, Japanese, (一社)日本臨床検査医学会


• Accurate measurement of edoxaban concentration after reversal by andexanet alpha

  Sho Shinohara, Jeyachelvi Pathmanathan, Natalia Marzak, Anthony De Oliveira, Hiroshi Matsuoka, Yoshinori Nakamura, Kohei Morimoto, Itsuko Sato, Dunois Claire

  ISTH 2025 Congress, Jun. 2025, English


• ニーズドリブン型バイオバンクにおける残余検体払出実績とタイムライン解析に基づく品質評価

  金 貞姫, 森本 耕平, 佐藤 伊都子, 岡野 隆一, 星 奈美子, 岡崎 葉子, 今西 孝充, 矢野 嘉彦, 中村 恵宣, 松岡 広

  日本臨床検査医学会誌, Oct. 2024, Japanese, (一社)日本臨床検査医学会


• ニーズドリブン型バイオバンクにおける残余血漿検体払出 実績と品質管理

  金 貞姫, 森本 耕平, 佐藤伊都子, 岡野 隆一, 星 奈美子, 鈴木 英夫, 中村 恵宣, 松岡 広

  第9回クリニカルバイオバンク学会シンポジウム, Aug. 2024, Japanese, 東北大学星陵オーディトリアム / 東北メディカル・メガバンク機構


• 利用者のニーズに応える “ニーズドリブン型”バイオバンクの取り組みについて

  中村恵宣

  第7回バイオバンク オープンフォーラム「バイオバンクが使われる ～あらためて利活用事例を考える～」, Aug. 2024, Japanese

  Invited oral presentation


• 神戸大学医学部附属病院バイオリソースセンターの取り組み

  中村恵宣

  関西医薬品協会 令和6年度第1回研究開発推進会議, Apr. 2024

  [Invited]


• Discovery of TA-8995 (obicetrapib) as a CETP Inhibitor

  HAYASHI Norimitsu, KUBOTA Hitoshi, NAKAMURA Yoshinori, YAMAMOTO Yasuo, SUGAHARA Masakatsu, HIGASHIJIMA Takanori, OOI Mariko, OKA Kozo

  日本薬学会年会要旨集(CD-ROM), 2019


• 世界最強の作用を有するCETP阻害剤TA-8995(obicetrapib)の創製

  林則充, 窪田均, 中村恵宣, 山元康王, 菅原正克, 東島孝典, 大井真利子, 岡幸蔵

  メディシナルケミストリーシンポジウム講演要旨集, 2018


• 特異的PDE5阻害薬の合成研究

  中村恵宣

  日本薬学会年会要旨集, 2002


• 特異的PDE5阻害作用を有するナフチリジノン誘導体の合成と薬理活性

  中村恵宣, 久保彰, 山元康王, 盛谷恭典, 東島孝典, 猿田邦夫, 小寺淳, 高木道乃, 浮田辰三

  日本薬学会年会要旨集, 2001


• Construction of Heterocyclic Compounds by Use of -Diazophosphonates: New One-pot Syntheses of Indole and Isocoumarin

  Yoshinori Nakamura, Tatsuzo Ukita

  18th International Congress of Heterocyclic Chemistry, 2001


• 特異的PDE5阻害作用を有するイソキノロン誘導体の合成

  中村恵宣, 久保彰, 山元康王, 高橋政巳, 盛谷恭典, 東島孝典, 猿田邦夫, 坂槙茂輝, 浮田辰三

  日本薬学会年会要旨集, 2000


• Synthesis of 1-aryl naphthalene lignan possessing the PDE V inhibitory effects.

  中村恵宣, 高橋政巳, 久保彰, 山元康王, 池尾富弘, 浮田辰三, 小寺淳

  日本薬学会年会要旨集, 1998


• Synthesis of a Novel Chiral 1,3-Benzoxazinone Auxiliary from L-Menthone and Its Application to Highly Diastereoselective Aldol Reactions.

  三宅努, 中村恵宣, 関雅彦, 大水博

  日本化学会講演予稿集, 1996


• 酸化還元系補酵素モデル5-デアザフラビン修飾オリゴデオキシヌクレオチドの合成と性質

  中村恵宣, 秋山泰身, 米田文郎, 田中圭

  日本薬学会年会要旨集, 1992

• テトラヒドロキノリン誘導体の製造方法

  岡本 征己, 櫻木 明, 森 敬和, 濱田 剛, 窪田 均, 中村 恵宣, 東島 孝典, 林 則充

  特願2009-502420, 29 Mar. 2007, 田辺三菱製薬株式会社, 特許第5275971号, 24 May 2013

  Patent right

  IRI


• コレステリルエステル輸送タンパク阻害剤としての三置換アミン化合物

  中村 恵宣, 林 則充, 東島 孝典, 窪田 均, 岡 幸蔵

  特願2008-535204, 30 Jan. 2007, 田辺三菱製薬株式会社, 特許第4943443号, 09 Mar. 2012

  Patent right

  IRI


• 医薬組成物

  中村 恵宣, 林 則充, 東島 孝典, 窪田 均, 岡 幸蔵

  特願2008-196568, 30 Jul. 2008, 田辺三菱製薬株式会社, 特開2009-051828, 12 Mar. 2009, 特許第4846769号, 21 Oct. 2011

  Patent right

  IRI


• 医薬組成物

  中村 恵宣, 林 則充, 東島 孝典, 窪田 均, 岡 幸蔵

  特願2008-196565, 30 Jul. 2008, 田辺三菱製薬株式会社, 特開2009-051827, 12 Mar. 2009, 特許第4834699号, 30 Sep. 2011

  Patent right

  IRI


• 医薬組成物

  窪田 均, 中村 恵宣, 東島 孝典, 山元 康王, 岡 幸蔵, 五十嵐 繁樹

  特願2006-261889, 27 Sep. 2006, 田辺三菱製薬株式会社, 特開2007-119451, 17 May 2007, 特許第4681526号, 10 Feb. 2011

  Patent right

  IRI


• テトラヒドロナフチリジン誘導体およびその製法

  窪田 均, 中村 恵宣, 東島 孝典, 山元 康王, 岡 幸蔵, 五十嵐 繁樹

  特願2006-534488, 01 Apr. 2005, 田辺三菱製薬株式会社, 特許第4633731号, 26 Nov. 2010

  Patent right

  IRI